Search results

Sort By:

Limit search:

Legitimacy and potential savings in automatic substitution of biological products in Poland, the example of insulin

100%

Wąż P., Gruchała K. A., Zimmermann A.

Acta Poloniae Pharmaceutica - Drug Research

2018

vol. 75

issue 5

1255-1263

Currently in Poland there is no regulation aiming at framing the complexity of substitution process arising at pharmacy level. In practice such process exists in variety type of products, both generic and biological scope. Lack of integrity in terms of this process between authorised medical professions who held it, might lead to further costs both for the health care system and patients. The aim of the study is to explain, that the economic advantage, which very often is the result of performed substitution process, in some types of products such as bio-logical ones, should be preceded with the decision of the treating physi-cian. Only then, in the cooperation between persons prescribing and dispensing certain medicinal product the process of substitution may fully use its potential of money saving along with the control over a certain patient. The study brings the yet unknown classification of dif-ferences in costs between actually performed automatic substitution of products containing human insulin in the pharmacy setting in Poland in four year period in five Voivodeships.

A policy view: gaps and weaknesses of substitution between biological products in law and economics dimension: the example of insulin

76%

Gruchała K. A., Waz P., Kawczak P., Zimmermann A., Wolnik B., Baczek T.

Acta Poloniae Pharmaceutica - Drug Research

2018

vol. 75

issue 4

1003-1015

The purpose of the study is to analyze the act of substitution between biological products. Diabetes mellitus notes the greatest increase in the projected causes of deaths globally till 2030. The proper drug substitution process may help to increase the control over the disease management. In this paper authors try to identify and explain the challenges for the health policies and legislations in emerging markets and low- and middle-income countries. Analysis of retrospective data covering prescribed-dispensed insulin products was performed. The study is based on the law and economics approach with the application of the planning theory and modeling. The study shows the scope of substitution process of insulin and highlights the necessity of univocal legal approach profiled for this therapy area. Prognosis of created base model indicates at constant presence of substitution process of insulin. Substitution is to bring financial savings for patients, it is yet however unknown whether savings arising from the act of purchase will still have positive impact on undertaken therapy process in long-term period. These findings may inform about important factors and how emerging markets and low- and middle-income countries can increase progress of the substitution process.

Refine search results

2 Acta Poloniae Pharmaceutica - Drug Research

2 2018

2 Gruchała K. A.

2 Zimmermann A.

1 Baczek T.

1 Kawczak P.

1 Waz P.

1 Wolnik B.

1 Wąż P.

Search results

Legitimacy and potential savings in automatic substitution of biological products in Poland, the example of insulin

A policy view: gaps and weaknesses of substitution between biological products in law and economics dimension: the example of insulin